头对头战胜诺华,抗过敏创新药企业即将IPO

健识局
Sep 05

8月21日,天辰生物递表港交所。这是一家成立不足5年的biotech公司,专注于过敏性疾病的生物药开发。核心产品LP-003是一款治疗过敏性鼻炎和慢性寻麻疹的IgE抗体药物,对标的是全球唯一一款上市的IgE药品:诺华的奥马珠单抗。奥马珠单抗2003年在美国上市,2024年全球销售额达到44.56亿美元,被誉为抗过敏“神药”。2017年奥马珠单抗在国内上市,米内网数据显示,2023年奥马珠单抗在国内...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10